Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC)
it takes time to build up your cellular stores
Favorable 97% Mixed 3% Unfavorable overall 0% Most reported benefits Benefits users selected when logging a favorable or mixed check-in
Studies have identified potential mediators that link gut dysbiosis and neurological disorders
External resources For researchers serious about optimizing their peptide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, dosing calculators, and a community of thousands who have navigated these exact reconstitution questions
By situating environmental justice within broader socio-technical governance processes, this study highlights how systemic inequities are embedded in policy frameworks and institutional practices